Deerfield-backed biotech emerges from stealth with gene therapy delivery platforms from Harvard and MIT

Lei Lei Wu

News Reporter

As a PhD student at Tufts, Dave Greenwald studied the use of adeno-associated virus (AAV) vectors to deliver gene therapies to people with retinitis pigmentosa …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Deerfield-backed biotech emerges from stealth with gene therapy delivery platforms from Harvard and MIT

Lei Lei Wu

News Reporter

Sign up to read this article for free.

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases

Deer­field-backed biotech emerges from stealth with gene ther­a­py de­liv­ery plat­forms from Har­vard and MIT

Lei Lei Wu

News Reporter

Sign up to read this article for free.

more like this

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

Deerfield-backed biotech emerges from stealth with gene therapy delivery platforms from Harvard and MIT

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

CagriSema’s weight loss data disappointed. What does Novo do next?

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

Novo Nordisk’s once-daily hemophilia drug Alhemo approved in US

Jim Wilson's GemmaBio raises $34M to commercialize gene therapies for rare diseases